UMSOP Scientist Receives American Lung Association Innovation Award to Advance Asthma Research

Ryan Pearson’s team will explore how engineered nanoparticles can safely retrain the immune system to reduce allergic airway inflammation.

By Pam Carder
October 2, 2025

Ryan Pearson, PhD, associate professor of pharmaceutical sciences (PSC) at the University of Maryland School of Pharmacy (UMSOP) and director of the School’s Bio- and Nano-Technology Center (BNTC), has received an Innovation Award from the American Lung Association to support his groundbreaking research into novel asthma therapies. The two-year, $150,000 grant will support the development of a nanoparticle-based platform designed to promote immune tolerance in allergic airway diseases.

Titled “Nanoparticles Targeting Immunometabolism to Induce Antigen-Specific Tolerance in Allergic Airway Disease,” the funded project explores a unique therapeutic approach that leverages biodegradable nanoparticles to modulate the immune system without broadly suppressing it.

“This research represents a major step forward in the treatment of asthma,” said Pearson. “Rather than suppressing the immune system as a whole, we’re working to train it by promoting tolerance to specific allergens. Our hope is that this can provide long-term relief to patients while reducing the risks associated with current therapies.”

Asthma affects millions of people worldwide and is often managed with treatments that carry significant side effects, including increased susceptibility to infections. Pearson’s research focuses on reprogramming immune cells by delivering allergens encapsulated in custom-engineered nanoparticles, leveraging natural metabolic pathways to reduce harmful inflammatory responses.

The project is a collaboration with co-investigator Achsah Keegan, PhD, professor of microbiology and immunology at the University of Maryland School of Medicine. PhD in PSC students in Pearson’s lab will also be actively involved, gaining hands-on experience in cutting-edge biomedical research.

“We are incredibly proud of Dr. Pearson’s achievement and the impact his work continues to have in the field of immunotherapy,” said Hongbing Wang, PhD, professor and interim chair of PSC. “His innovative approach exemplifies the type of translational science we strive for – research that not only advances science but holds real promise for improving patient outcomes.”

Pearson’s research will be conducted using BNTC’s advanced facilities, including labs for polymer synthesis, nanoparticle formulation, and immunological testing.

“This award underscores the importance of investing in science that bridges basic research and clinical application,” added Pearson. “It’s an honor to have the support of the American Lung Association as we work to redefine asthma treatment.”

The funded period began July 1, 2025, and runs through June 30, 2027.

Related News Stories

More Stories About: Bio- and Nano-technology PSC Research Ryan Pearson